Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients

Journal of the American Society of Nephrology

Volumn 7, Issue 2, 1996, Pages 325-330

  Kletzmayr, Josef ^a   Kotzmann, Harald ^a   Popow Kraupp, Theresia ^b   Kovarik, Josef ^a   Klauser, Renate ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Acyclovir; CMV; Disease; Infection; Prevention; Renal transplantation

Indexed keywords

ACICLOVIR; AZATHIOPRINE; CYCLOSPORIN; CYCLOSPORIN A; METHYLPREDNISOLONE; OKT 3; PREDNISOLONE; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT REJECTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TRANSPLANTATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029927762     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Ho M: Cytomegalovirus: Biology and Infection. 2nd Ed. New York: Plenum; 1991:249-252.
2. Metselaar HJ, Weimar W: Cytomegalovirus infection and renal transplantation. J Antimicrob Chemother 1989: 23[Suppl E]:37-47.
3. Weir MR, Irwin BC, Maters AW, et al.: Incidence of cytomegalovirus disease in cyclosporine-treated renal transplant recipients based on donor/recipient pretransplant immunity. Transplantation 1987;43:187-193.
4. Bia MJ, Andiman W, Gaudio K, et al.: Effect of treatment with cyclosporine versus azathioprine on incidence and severity of cytomegalovirus infection posttransplantation. Transplantation 1985;40:610-614.
5. Klauser R, Zlabinger GJ, Traindl O, et al.: Influence of immunosuppressive therapy on infectious complications in renal transplant recipients. Transplant Proc 1992;24: 292-294.
6. Hibberd PL, Tolkoff-Rubin NE, Cosimi AB, et al.: Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation 1992;53:68-72.
7. Fryd DS, Peterson PK, Ferguson RM, Simmons RL, Balfour HH, Najarian JS: Cytomegalovirus as a risk factor in renal transplantation. Transplantation 1980; 30:436-439.
8. Weir MR, Irwin BC, Maters AW, et al.: Morbid outcome of cytomegalovirus-negative transplant recipients receiving cytomegalovirus-positive kidneys. Transplant Proc 1987: 19:2137-2141.
9. Smiley ML, Wlodaver CG, Grossman RA, et al.: The role of pretransplant immunity in protection from cytomegalovirus disease following renal transplantation. Transplantation 1985:40:157-161.
10. Rocha E, Campos HH, Rouzioux C, et al.: Cytomegalovirus infections after kidney transplantation: Identical risk whether donor or recipient is the virus carrier. Transplant Proc 1991:23:2638-2640.
11. De Clercq E: Antivirals for the treatment of herpesvirus infections. J Antimicrob Chemother 1993:32[Suppl A]:121-132.
12. Balfour HH, Chace BA, Stapleton JT, Simmons RL, Fryd DS: A randomized, placebo controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989;320: 1381-1387.
13. Chitwood KK, Heim-Duthoy KL, Ney AL, Kasiske BL: Questionable benefit of prophylactic acyclovir in renal transplant recipients at high risk for cytomegalovirus disease. Clin Transplant 1993;7:320-324.
14. Wong T, Lavaud S, Toupance O, et al.: Failure of acyclovir to prevent cytomegalovirus infection in renal allograft recipients. Transpl Int 1993;6:285-289.
15. Legendre C, Ducloux D, Ferroni A, et al.: Acyclovir in preventing cytomegalovirus infection in kidney transplant recipients: A case-controlled study. Transplant Proc 1993:25:1431-1433.
16. Bailey TC, Ettinger NA, Storch GA, et al.: Failure of high-dose oral acyclovir with or without immune globulin to prevent primary cytomegalovirus disease in recipients of solid organ transplants. Am J Med 1993;95:273-278.
17. Middeldorp JM, Jongsma J, ter Haar A, Schirm J, The TH: Detection of immunoglobulin M and G antibodies against cytomegalovirus early and late antigen by enzyme-linked immunosorbent assay. J Clin Microbiol 1984;20:763-771.
18. Sererat MN, Schifano JV, Lau P, Beikert E, Shumbra NA, Nankervis GA: Evaluation of cytomegalovirus (CMV) antibody screening tests for blood donors. Am J Clin Pathol 1986:86:523-526.
19. Roenhorst HW, Tegzess AM, Beelen JM, Middeldorp JM, The TH: HLA-DRw6 as a risk factor for active cytomegalovirus but not for herpes simplex virus infection after renal allograft transplantation. Br Med J 1985; 291:619-622.
20. Stagno S, Reynolds DW, Smith RJ: Use of isolated nuclei in the indirect flourescent-antibody test for human cytomegalovirus infection: Comparison with microneutralization, anticomplement, and conventional indirect flourescent-antibody assays. J Clin Microbiol 1978:7: 486-489.
21. Gleaves CA, Smith TF, Shuster EA, Pearson GR: Rapid detection of cytomegalovirus in MRC-5 Cells inoculated with urine specimens by using low-speed centrifugation and monoclonal antibody to an early antigen. J Clin Microbiol 1984;19:917-919.
22. Popow T, Kunz C: Dedection of CMV in clinical specimens by virus isolation and by monoclonal antibody against the early nuclear antigen. J Med Virol 1988;24: 275-282.
23. van der Bij W, Torensa R van Son WJ, et al.: Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes. J Med Virol 1988:25:179-188.
24. Klauser R, Kotzmann H, Wamser P, et al.: Experience with a new monoclonal antibody against PP 65 for early diagnosis of CMV-infection in renal transplantation. In: Andreucci VE, Dal Canton A, Eds. Current Therapy in Nephrology 1992. Milan: Wichtig Editore; 1993:17-21.
25. Plotkin SA, Starr SE, Friedman HM, et al.: Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. Ann Intern Med 1991;14:525-531.
26. Glowacki LS, Smaill FM: Meta-analysis of immune globulin prophylaxis in transplant recipients for the prevention of symptomatic cytomegalovirus disease. Transplant Proc 1993:5:1408-1410.
27. Snydman DR, Rubin RH, Werner BG: New developments in cytomegalovirus prevention and management. Am J Kidney Dis 1993;21:217-228.
28. Pakkala S, Salmela K, Lautenschlager I, Ahonen J, Häyry P: Anti-CMV hyperimmune globulin prophylaxis does not prevent CMV disease in CMV-negative renal transplant recipients. Transplant Proc 1992;24:283-284.
29. So S, Mayo C, McCullogh C, et al.: Cytomegalovirus prophylaxis in pediatric renal transplant recipients. Transplant Proc 1993;25:1414-1415.
30. Kovarik J, Mayer G, Pohanka E, et al.: Adverse effect of low-dose prophylactic human recombinant leukocyte interferon-alpha treatment in renal transplant recipients. Transplantation 1988:45:402-405.
31. Ackermann JR, LeFor WM, Weinstein S, et al.: Four-year experience with exclusive use of cytomegalovirus antibody (CMV-Ab)-negative donors for CMV-Ab-negative kidney recipients. Transplant Proc 1988; 20[Suppl 1]:469-471.
32. Shakleton CR, Keown PA, Landsberg DN, et al.: The impact of donor/recipient matching for cytomegalovirus compatibility or identity on the incidence of disease and outcome following renal transplantation. Transplant Proc 1991;23:1350-1351.
33. Ramos EL, Kasiske BL, Alexander SR, et al.: The evaluation of candidates for renal transplantation. Transplantation 1994;57:490-497.
34. Schroeder TJ, First MR: Cytomegalovirus infection and the role of ganciclovir prophylaxis in transplant recipients [Review]. J Nephrology 1994;7:77-88.
35. Conti DJ, Freed BM, Gruber SA, Lempert N: Prophylaxis of primary cytomegalovirus disease in renal transplant recipients. Arch Surg 1994;129:443-447.
36. van Son WJ, van den Berg AP, The TH, Tegzess AM: Preemptive therapy with ganciclovir for early high-risk CMV infection allows effective treatment with antithymocyte globulin of steroid-resistant rejection after renal transplantation. Transplant Proc 1993:25:1436-1438.
37. MacDonald AS, Belitsky P, Cohen A, Lee S: Cytomegalovirus disease prophylaxis in seronegative recipients of kidneys from seropositive donors by combination of cytomegalovirus-hyperimmune globulin and low-dose acyclovir. Transplant Proc 1991:23:1355-1356.
38. Rubin RH: The indirect effects of cytomegalovirus infection on the outcome of organ transplantation [Editorial]. JAMA 1989;261:3607.
39. Boyce NW, Hayes K, Gee D, et al.: Cytomegalovirus infection complicating renal transplantation and its relationship to acute transplant glomerulopathy. Transplantation 1988:45:706-709.
40. Tenschert W, Dittmer R, Harfmann P, et al.: Vascular rejection of renal allografts is linked to CMV IgG positive organ donor. Transplant Proc 1991;23:2641-2642.
41. von Willebrand E, Pettersson E, Ahonen J, Häyry P: CMV infection, class II antigen expression, and human kidney allograft rejection. Transplantation 1986;42: 364-367.
42. Richardson WP, Colvin RB, Cheeseman SH, et al.: Glomerulopathy associated with cytomegalovirus viremia in renal allografts. N Engl J Med 1981;305:57-63.
43. Morris DJ, Martin S, Dyer PA, Hunt L, Mallick NP, Johnson RWG: HLA mismatching and cytomegalovirus infection as risk factors for transplant failure in cyclosporin-treated renal allograft recipients. J Med Virol 1993;41:324-327.
44. Vasquez EM, Sanchez J, Pollak R, Vrahnos D, Fabrega AJ, Maddux MS: High-dose oral acyclovir prophylaxis for primary cytomegalovirus infection in seronegative renal allograft recipients [Brief Communication]. Transplantation 1992;55:448-450.
45. Freie HMP: Pharmakologie von Ganciclovir. Med Klin 1992;87[Suppl 1]:20-23.
46. Fletcher CV, Englund JA, Edelman CK, Gross CR, Dunn DL, Balfour HH: Pharmacologic basis for high-dose oral acyclovir prophylaxis of cytomegalovirus disease in renal allograft recipients. Antimicrob Agents Chemother 1991; 35:938-943.
47. Weller S, Blum MR, Smiley ML: Phase I pharmacokinetics of the acyclovir prodrug, valacyclovir. Antiviral Res 1993;20[Suppl 1]:144.